Antibacterial drug discovery is moving from largely unproductive high-throughput screening of isolated targets in the past decade to revisiting old, clinically validated targets and drugs, and to classical black-box whole-cell screens. At the same time, due to the application of existing methods and the emergence of new high-throughput biology methods, we observe the generation of unprecedented qualities and quantities of genomic and other omics data on bacteria and their physiology. Tuberculosis (TB) drug discovery and biology follow the same pattern. There is a clear need to reconnect antibacterial drug discovery with modern, genome-based biology to enable the identification of new targets with high confidence for the rational discovery of new drugs. To exploit the increasing amount of bacterial biology information, a variety of in silico methods have been developed and applied to large-scale biological models to identify candidate antibacterial targets. Here, we review key concepts in network analysis for target discovery in tuberculosis and provide a summary of potential TB drug targets identified by the individual methods. We also discuss current developments and future prospects for the application of systems biology in the field of TB target discovery.
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), was declared a global health emergency almost 20 years ago. Yet it continues to be the leading cause of death from a single bacterial pathogen. 1 According to the report 'Global tuberculosis control 2012', published by the WHO, 8.7 million new cases of TB (13% of which are co-infections with HIV) and 1.4 million TB-related deaths have been reported worldwide in 2011.
Resistance and persistence are the major issues in TB control. 2 The latest statistics from the WHO revealed that annually there are estimated to be 440 000 new cases of multidrug-resistant TB (MDR-TB), defined as resistance to the two most efficacious frontline drugs, isoniazid and rifampicin. Extensively drug-resistant TB (XDR-TB), which shows additional resistance to fluoroquinolones and an injectable drug (kanamycin, capreomycin or amikacin), is increasing. Excellent reviews on the molecular mechanisms of resistance can be found elsewhere. 3, 4 Patients infected with drug-resistant strains of MTB are prone to treatment failure, thus posing a risk of disseminating resistant strains in their communities. 5 Persistence of infection despite extensive chemotherapy is the second major issue in TB control. While drug-susceptible TB requires 6 -9 months of combination therapy to achieve cure, MDR-TB and XDR-TB treatments take years. Although a few new candidates have recently entered early clinical development, there remains an urgent medical need for the discovery and development of new antimycobacterials with new mechanisms of action to keep drug resistance at bay and develop faster-acting regimens to reduce treatment duration and hence increase compliance. 6 During the last 5 years the field of antibacterial drug discovery has changed dramatically regarding the discovery strategies, and antimycobacterial drug discovery is no exception. 7, 8 Target-based high-throughput screening has been largely disappointing. Understanding of this lack of success has increased and some lessons learnt refer to target selection criteria, composition and diversity of chemical libraries, as well as screening strategies. The apparently rational genomics approach to antibacterial drug discovery initiated in the late 1990s (high-throughput screening of genetically essential targets) has been replaced by a diverse set of discovery strategies, including going back to classical phenotypic whole-cell screens, revisiting old, clinically validated targets, and re-evaluating old, abandoned compounds and drugs. 8 De novo target-based antibacterial drug discovery has so far not been successful, explaining the current trend to move back to whole-cell screens and old targets and drugs. However, cell-based lead finding and optimization, although feasible, is a black box approach, excluding the use of several modern medicinal chemistry approaches, such as structure-based design and fragment-based screening. Going back to old targets and compounds is useful and pragmatic, but might not yield sufficient compounds with new mechanisms of action to feed the pipelines. Therefore, there is clearly a need to reconnect modern genome biology with drug discovery to provide the basis for rational, target-based programmes that can make full use of modern lead finding and optimization tools. 9 Emerging themes in target identification are chemical target validation with a tool compound in vitro 9 and genetic target validation via silencing in animal models. 10, 11 Another interesting approach is the dissection of the extended mechanism of action of existing cidal antibacterials for the identification of compoundinduced intracellular bacterial cell death pathways. 12 In addition to these probe-driven 'throw a spanner in the works' approaches, systems biology approaches, incorporating bioinformatics and computational modelling of biological networks, are becoming more capable of the prediction of potential candidate targets that can be validated experimentally. 13, 14 While the reductionist approach has been, and will continue to be, an essential part of biological research, the increasing amounts of data on genomics and physiology of various organisms generated by high-throughput technology has effectively brought an end to 'naive reductionism' and has led to the birth of systems biology. 15 The key contribution of systems biology is the elucidation of emergent properties resulting from a comprehensive analysis of complex large-scale biological interaction networks. 16 In order to integrate various forms of experimental and literature data for the construction and analysis of biological network models, the use of computational tools and bioinformatics is indispensable. This leads to a concomitant trend of rapid development of in silico methods for data and model analyses. In the field of drug discovery, many researchers have proposed novel computational methodologies to aid various stages of drug discovery, including target identification, drug design and lead optimization. Here, we review and discuss current in silico target identification approaches and provide an overview of candidate drug targets identified so far for M. tuberculosis.
Construction of biological network models
In systems biology, in silico models can be generally classified as mathematical or computational models depending on whether they are based on a set of mathematical equations or an algorithm codifying rules for altering biological behaviour, respectively. 17 Network models typically describe one of the following biological properties: transcription factor (TF) binding, protein -protein interaction (PPI), protein phosphorylation and metabolic interaction. 18 These models play an important role in providing a cost-effective platform to interpret experimental observations, making it possible to gain more insight into the fundamental characteristics and emergent properties of complex living systems. To harness the capabilities of in silico models, we have to know how they can be constructed. The prerequisite for constructing these network models is the availability of biological information, which can be found through literature mining or obtained by conducting wetlaboratory experiments. Well-organized databases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), 19 MetaCyc 20 and the National Center for Biotechnology Information (NCBI) resources, have greatly facilitated the process of procuring biological information and experimental data. Notably, the TB Database provides users with a one-stop solution for accessing omics data, biological pathways, and gene and protein functions information specific to M. tuberculosis. 21 Given the abundance of resources available, the researcher can then choose to construct the in silico model using the top-down or bottom-up approach, 22 as illustrated in Figure 1 .
In the top-down approach, information on biomolecular interactions in the network model is inferred from high-throughput experimental data using statistical methods such as multivariate data analysis and probabilistic methods. 23 Therefore, the inferred network model is considered complete in the sense that it captures all possible in vivo behaviour observed from high-throughput experimental data, such as microarray-based transcriptome analyses. An example of a model constructed using the top-down approach is the genetic Bayesian network, which is constructed using Bayesian statistics to infer the existence of gene interactions, leading to the discovery of genetic regulatory pathways. Such a network can then be used to identify regulatory pathways that are perturbed by drugs, also known as 'drug active pathways', and the corresponding druggable genes as potential targets for in vivo validation. 24 In the case of antimycobacterial drug discovery, some notable studies adopting the top-down approach have been reported by Rachman and co-workers, 25 where the authors infer functional associations of proteins using the following methods: the Rosetta Stone method, which classifies proteins with homologues that are fused into a single chain in other organisms as functionally related;
26 the phylogenetic profiling method, which assigns functional links between proteins having homologues in the same subset of organisms; 27 the conserved gene neighbour method, which classifies genes that are in close proximity in the genomes of multiple organisms to be functionally related; 28, 29 and the operon method, which calculates nucleotide distances between genes and classifies genes in close proximity into potential operons carrying out the same biological function. 30 Interestingly, the operon method has been specifically developed to elucidate protein functional linkages based the genome organization of M. tuberculosis genes. 30 Analysis of constructed network models has allowed researchers to identify linoleoyl-CoA desaturase (Rv3229c), targeted by the drug thiourea isoxyl, 25 and propose novel drug targets, such as Rv1503c, Rv1504c (both associated with the targets of ethambutol in the arabinogalactan biosynthesis pathway) and Rv1879 (associated with glutamine synthase without human homologue). 30 These studies have clearly presented the top-down approach as a promising strategy to construct models for drug target identification. However, we have to be aware that the inferred molecular interactions in these models may be far from the true biological mechanism. Hence, further analyses are required to ascertain the actual cellular mechanisms behind the experimental observations.
In order to construct a mechanism-based model, the bottom-up approach will be more suitable as it attempts to elucidate overall systems behaviour or emergent properties through the reconstruction of interaction network models based on well-studied molecular interactions. Information on individual molecular interactions, including TF binding, PPI and enzymatic metabolic reactions, can be found in pathway databases such as TRANSFAC, 31 STRING, 32 KEGG 19 and MetaCyc. 20 The accessibility and availability of these databases have resulted in the publication of numerous MTB interaction network models. At the gene regulatory level, the MycoRegNet database is a noteworthy contribution towards reconstruction of MTB gene regulatory networks based on well-characterized Review regulatory interactions of gene orthologues found in the phylogenetically related Corynebacterium glutamicum. 33 While the quality of MycoRegNet may continue to be improved through further model curation and experimental validation, it is already able to capture several important regulatory mechanisms of cellular metabolism and to propose potential targets associated with virulence. At the PPI level, in silico analyses of the reconstructed networks have resulted in the identification of potential targets, such as Rv1354c, a hypothetical protein associated with extracellular signalling, 34 and histidinol-phosphate aminotransferase (HisC1). 35 Lastly, at the cellular metabolism level, the earliest reported metabolic model of MTB was that of the mycolic acid biosynthesis pathway, which was used to elucidate the essentiality of different mycolates for the survival of the pathogen. 36 This work was followed by the reconstruction of two genome-scale metabolic network (GSMN) models of MTB: GSMN-TB and iNJ661. 37, 38 It is noted that GSMN-TB was reconstructed based on genome synteny with Streptomyces coelicolor, while iNJ661 was reconstructed directly based on the MTB genome. 39 Hence, some minor discrepancies between the two models are expected. Nonetheless, both models were capable of identifying validated drug targets, such as inhA, fasI and embAB. The unique feature of GSMN-TB is that it has been implemented as an interactive web-based model that allows users to carry out metabolic simulations online (http://sysbio3.fhms.surrey. ac.uk/). On the other hand, iNJ661 was reported to demonstrate how the identification of sets of metabolic reactions with highly correlated fluxes, known as 'hard-coupled reaction sets', can enable us to identify potential metabolic targets that belong to the sets containing essential metabolic reactions. Following the reconstruction of these two GSMNs, a study of the integration of GSMN analysis with structural bioinformatics and molecular modelling to characterize the TB drugome for drug target identification has been reported. 40 In addition, there is also a report on the integration of the mycolic acid sub-model into the GSMN-TB model to assess the effects of drugs on mycolic acid biosynthesis using the E-flux method, which incorporates gene expression data in the analysis of metabolic fluxes. 41 In silico analysis techniques for target discovery
In the previous section, we have briefly delineated how in silico biological network models can be constructed and some of their contributions to the identification of drug targets in MTB. Now, we will further examine the different computational analyses that can be applied to the models to elucidate potential drug targets. By classifying the biological network models into interaction-based (IB), constraint-based (CB) or mechanism-based (MB) models, as suggested by Stelling, 42 we will proceed with the discussion of in silico analysis techniques with respect to their applicability to each type of model. A summary of reported in silico analysis methods used for drug targeting in MTB is presented in Table 1 . 
Analysis of IB models
An IB model can be considered as the most preliminary type of network model, in which interactions of the biomolecules are simply reflected as a mesh of nodes and edges. The nodes can represent genes, proteins, small molecules, drugs, or any other biological entity capable of interactions in the system being modelled, while edges connecting the nodes represent biological interactions, including phosphorylation, activation, inhibition and biochemical reactions. In addition, the edges can be associated with attributes such as weights and directionality to provide information on the hierarchy of effects. 43 Since most IB networks only describe the existence of biological interactions, analyses of such models are largely based on the network structure, where network topological analysis and graph theory can be employed. Definitions of the commonly used topological parameters used for the analysis of biological networks can be found in Table 2 .
A study that is solely based on network topological analysis to characterize MTB drug resistance has been reported by Raman and Chandra. 44 By assigning scores to nodes and edges in the PPI network based on network measures, including betweenness and the shortest path (Table 2) , pathways to efflux pumps, cytochromes, the SOS response for DNA damage and horizontal gene transfer were found to be implicated in drug resistance pathways. To more effectively tackle the issue of drug resistance, the concept of the 'co-target' was introduced; a co-target is a protein that can effectively circumvent drug resistance when it is inhibited simultaneously with the conventional primary drug target. Consequently, proteins including DNA E1 (Rv1547), RecA (Rv2737c) and Rv0823c were identified as potential co-targets that can be used to combat drug resistance. 44 Similarly, topological analysis has also been used to characterize the MTB transcriptional regulatory network, revealing that there is only a small number of TF 'hubs' while most TFs regulate few or no targets, hinting at the existence of points of fragility that can be targeted to disrupt vital processes of the pathogen. 45 By further defining sub-networks called 'origons' and quantifying gene expression variation using the NetResFun computational procedure, Balazsi and co-workers 45 identified dosR, hrcA and sigD as early responders and furB, nadR, sigC and sigE as late responders to cell growth arrest. Since these regulators are implicated in the transition between replicative and dormancy states, they can be effective drug targets to nullify MTB's persistence phenotype. More recently, the analysis of protein interaction networks combined with structural modelling has also been used to characterize the resistome, which consists of genes responsible for drug resistance against antibiotics. 46 In that study, the acetyltransferases that detoxify antibiotics by acetylation were identified as drug co-targets to combat MDR and XDR tuberculosis, thus demonstrating a promising framework for rational drug targeting. Experimentally validated to be targeted by a known drug (in parentheses), reported in the DrugBank database and previous review papers. 69 -71 
Review
At the cellular metabolism level, topological analysis of a metabolome-based reaction network of MTB has been used to identify highly connected hubs and alternative metabolic pathways that can be further exploited for drug targeting. 47 It is noted that most IB metabolic network models account for the directionality of node interaction as information on metabolic reaction reversibility is readily available either from literature reports or by calculation of reaction thermodynamics. Thus, by considering the directionality of information in the metabolic network, we can identify critical junctions, called 'chokepoints', which are defined as reactions that uniquely consume and/or produce certain metabolites. 48, 49 The inactivation of a chokepoint can lead to growth inhibition as a result of either the intracellular accumulation of a toxic metabolite, if the chokepoint is an enzyme that uniquely consumes toxic substrate, or the starvation of an essential biomolecule, if the chokepoint is an enzyme that uniquely produces the essential metabolite. In this sense, chokepoints are crucial points of control within the metabolic network that can serve as potential drug targets. Subsequent to the introduction of the chokepoint concept, several MTB target studies have incorporated chokepoint analysis to identify potential metabolic drug targets. 35, 50, 51 A noteworthy contribution was that of Raman and co-workers, 52 which integrated chokepoint analysis, CB analysis and other structural comparison methods to form a systematic drug target identification pipeline.
Analysis of CB models
By introducing constraints based on reaction stoichiometry, reversibility and flux capacity to an IB model, we can characterize the feasible set of achievable flux distributions of the organism using CB flux analysis. The resulting CB models are usually applied to describe the metabolic network where the distribution of metabolic resources strongly influences the cellular physiology. Since reaction stoichiometry and reversibility are usually well-characterized physicochemical invariants, the set of feasible metabolic states corresponding to the defined CB model will be able to describe all possible cellular behaviours. Nonetheless, it is desirable to obtain a unique internal flux map that accurately describes a particular metabolic state of interest. Hence, flux balance analysis (FBA) has been widely used to calculate an optimum flux distribution under pre-specified genetic and environmental conditions. 53 The basic working principle of FBA is the assumption that the organism attempts to optimize a certain cellular objective, usually cell growth, while satisfying mass balance under a pseudo steady-state condition. The resulting mathematical formulation of this problem can be expressed as a linear programming problem as follows:
where Z is the cellular objective, c j is a pre-specified coefficient for reaction j indicating the relative importance of maximizing its flux in describing a particular biological condition, S ij refers to the amount of metabolite i consumed or produced in reaction j, and v j is the flux of reaction j. The parameters a j and b j indicate the upper and lower flux limits of reaction j, which can be determined experimentally by measuring the V max of enzymes or calculated based on thermodynamic properties. 54 Apart from the conventional assumption that the cell maximizes its biomass or cell growth, several studies have been carried out to investigate the relevance 
The degree distribution of biological networks typically follows the power law, where there are only a few highly connected hubs. Such 'scale-free' networks exhibit robustness against accidental node failures and their potential points of fragility lie on the highly connected hubs. Hence, a potential method of rational drug targeting is to identify highly connected nodes in biological networks. Shortest path min(d ij ) Assuming that the living system evolves to utilize the most efficient pathways to carry out its biological function, the computational evaluation of the shortest path between nodes is likely to represent the in vivo pathway that is taken for processes like transcriptional regulation, cell signalling and metabolism. Therefore, the intermediate biomolecules lying in the essential pathways are likely to be potential drug targets. Betweenness
Betweenness can be viewed as an extension to the shortest path measure such that intermediate biomolecules that participate in a larger number of shortest pathways are given a higher score. Hence, drug targets can be prioritized based on the betweenness scores.
Clustering coefficient
Percentage of existing links in the neighbourhood of one node.
a ij , interaction between nodes i and j, usually 0 for no interaction and 1 for existence of interaction; b l , betweenness measure of node l; d ij , pathway distance between nodes i and j; k i , total numberof interaction partners for node i; N k , total numberof nodes of k degrees; N, total number of nodes in the network; P(k), degree distribution of network; p ij , total number of shortest paths between nodes i and j; p ij (l), total number of shortest paths between nodes i and j passing through node l.
The biological significance is discussed in the context of identifying drug targets in MTB to disrupt its vital cellular functions.
Review 2705 JAC of other cellular objectives and how to select an objective function appropriately. 55 -57 Further developments of FBA to describe genetically perturbed conditions include the minimization of metabolic adjustment (MOMA) 58 and regulatory on/off minimization (ROOM). 59 The metabolic flux distribution generated by any of the FBA methods can then be validated by isotope-labelling experiments, known as 13 C metabolic flux analysis. 60 Such an analysis has recently been carried out on MTB to uncover the role of potential drug target isocitrate lyase in carbon dioxide fixation, which aids the pathogen's survival in the human host. 61 Under the FBA framework, potential targets are identified as essential genes or synthetic lethal genes, corresponding to single deletions or multiple gene deletions, respectively, which yield no cell growth. In a unique study focused on the mycolic acid pathway, mycolic acid biosynthesis was used as the cellular objective instead of cell growth to identify potential drug targets. 36 To further enhance the accuracy of model predictions, gene expression data can be incorporated into FBA, as demonstrated by the E-flux method, whereby reaction fluxes are forced to correlate with gene expression levels. 41 In addition, the concept of flux-sum analysis, which evaluates the effect of metabolite turnover rates on cellular metabolism, can be used to identify essential metabolites that can be targeted to disrupt the normal metabolic functions of the organism.
62,63

Analysis of MB models
The MB model is a further development of the CB model whereby kinetic parameters are incorporated to describe temporal changes in the concentration of biomolecules within the system, providing a more realistic description of cellular dynamics. Thus, in contrast to CB models, MB models enable the researcher to analyse the sensitivity of the system to changes in metabolite concentrations. 42 MB models usually express the kinetics of biomolecular interactions as differential equations based on the mass action law. Regarding the aspect of cellular metabolism, assumptions can be made to obtain the more simplified Michaelis -Menten equations that describe different forms of enzyme activation and inhibition kinetics. While the analysis of CB models involves solving an optimization problem, MB model analysis requires the capability to solve a system of differential equations that, in most cases, is more computationally intensive. Nonetheless, results of MB model analysis can provide a greater insight into the behaviour of targets, as demonstrated by the kinetic modelling study of Figure 2 . Drug identification workflow of targetTB. 52 Protein interaction and metabolic networks are constructed based on information from various databases. Drug targets are identified by analysing the networks for points of fragility that correspond to proteins vital for MTB's survival. Subsequently, the targets are prioritized according to their potential for druggability and likelihood of causing side effects in the human host.
Review tricarboxylic acid (TCA) cycle and glyoxylate bypass in MTB, where perturbation of kinetic parameters revealed that the competitive inhibition of isocitrate lyase coupled with increased activation of isocitrate dehydrogenase can be a potential strategy against persistent MTB. 64 Nonetheless, in most cases there are insufficient experimental data or literature reports to construct a genome-scale MB model. Thus, to harness both the modelling simplicity of CB models and the insight into dynamic behaviour provided by MB models, an integration of MB and CB models has been attempted to study the dynamic effects of perturbing potential drug targets, where the in silico model was shown to be able to predict the in vivo dynamic behaviour of growth inhibition resulting from increasing concentrations of 5 ′ -O-(N-salicylsulfamoyl) adenosine. 65 
Conclusion and future perspectives
The capability to generate high-throughput experimental data and the huge repository of biological knowledge on biomolecular interactions found in various databases has greatly facilitated the construction of comprehensive biological network models. Analysis of these models can provide us with insightful knowledge on the organism's physiology that can be harnessed for target discovery, as evident in the numerous antimycobacterial drug targeting studies reported in recent years. In many cases, network model analysis was used as the first step in target identification to filter out candidates from the myriad biomolecules in MTB, followed by further analyses at the molecular structural level to assess the candidate's potential as a drug target based on criteria that include druggability, the presence of the human homologue, and the likelihood of causing adverse effects in the human host. 51 Previous in silico studies were able to identify targets, such as inhA (Rv1484), kasA (Rv2245) and embAB (Rv3794 and Rv3795), which are known to be targeted by existing drugs (Table 1) . Interestingly, all these validated targets were identified by analysing a CB model associated with MTB metabolism, thus implicating the metabolic disruption of pathogens as an effective and practical approach. Nevertheless, the analysis of other biological networks involving PPI and TF binding should not be understated as they can capture other important regulatory mechanisms. This allows us to identify novel potential targets leading to systems-wide disruption of MTB cellular physiology through signalling cascades. 66 A noteworthy contribution to building a systematic drug target identification pipeline would be targetTB, 52 as illustrated in Figure 2 . Although the current targetTB pipeline does not consider MB analysis of the physiology of MTB, it lays a good foundation for rational in silico drug targeting. Hence, a promising future development of the pipeline will be the incorporation of host -pathogen interaction analysis, which was demonstrated in previous work that identified hyaluronan synthase in macrophages as a potential drug target to inhibit MTB infection. 67 In addition, the application of MB model analysis to the study of robustness and fragility of network is expected to enable the discovery of novel synthetic lethal combinations. 68 As the current practice for multiple drug target identification typically involves the in silico removal of gene functions, the use of MB models to evaluate the effects of moderate attenuation, instead of complete elimination, of multiple gene functions will probably lead to the discovery of novel drug targets.
Finally, it should be noted that despite the utility and costeffectiveness of in silico analysis, the accuracy of its results is heavily reliant on the quality of the data used to build the biological network models. A huge amount of manual effort is required to ensure that the information on gene functions and various biomolecular interactions is accurate. From this aspect, collaborations between multiple research groups are crucial to provide the necessary manpower to successfully execute a project that requires large-scale data curation. A crowd-sourcing effort, which is part of the Open Source Drug Discovery (OSDD) Project, demonstrated how the concerted efforts of a huge research community can curate the interactome of MTB to identify novel drug targets. 66 This consortium effort may also involve experimentalists in the future to further validate new hypotheses generated by in silico analysis, thus establishing a comprehensive platform technology for drug discovery. The synergy created by such a collaborative effort is expected to deliver the urgently needed attractive and validated targets to put antimycobacterial drug discovery back on track.
